Insider Cluster (2 insiders) ·Filed Aug 5, 2026

MAZE

Maze Therapeutics, Inc.
NEUTRAL
Impact 3/10
Horizondays Processed1mo ago
Insider cluster: 2 insiders, $1.0M total
Actionable Insight • Neutral

The $1.0M insider sell cluster is small relative to market cap and likely reflects routine portfolio diversification or tax planning rather than a bearish view on the business. Monitor for any upcoming earnings or pipeline updates that could explain the timing, but the low proportionality (0.07%) and weak historical calibration for MAZE reports suggest no immediate trading action is warranted.

DirectionNeutral
Confidencemedium
Horizondays
Latest settled — T+20d
MAZE ▼ -3.92% at T+20d
NEUTRAL call ✗ call lost -3.92% · α vs SPY -3.32% · entry $27.81 → $26.72
Next anchor: T+60d in 26d
Latest observation: T+38 -3.56% FF3 residual α
Entry anchored
Aug 4, 04:36 PM ET
via 1-min bar
T+1d
+2.59%
call +2.59% · α +2.75%
$28.53
settled 8w ago
T+5d
-1.01%
call -1.01% · α -1.36%
$27.53
settled 7w ago
T+20d
-3.92%
call -3.92% · α -3.32%
$26.72
settled 4w ago
T+60d
—
call — · α —
—
in 26d

Price Chart

Loading chart...

Executive Summary

CEO Jason Coloma and CSBO Atul Dandekar sold a combined $1.0M in MAZE shares over a 7-day window, with the CEO alone selling 30.3K shares worth $810K on August 3. This cluster represents 0.07% of the $1.5B market cap — a modest but notable insider sell-off at a time when the stock is near its highs and the analyst consensus is 94% bullish. The historical calibration shows past MAZE reports have underperformed (avg T+20 alpha -4.22%, 30% win rate), and the cluster's dollar value is below the 0.1% threshold for materiality, suggesting this is routine liquidity-driven selling rather than a bearish signal.

Key Financial Metrics

Direction
selling
Total Value
$1.0M
Insiders
2

Key Facts

  • CEO Jason Coloma sold 30,304 shares at $26.71 for $810K on 2026-08-03
  • CSBO Atul Dandekar sold 7,100 shares at $27.31 for $194K on 2026-07-29
  • Total cluster value: $1.0M, representing 0.07% of $1.5B market cap
  • Both sales are open-market (code S) — no 10b5-1 plan noted
  • Stock is trading near $27, with 94% analyst bullish consensus

Financial Impact

Insider sales of $1.0M represent 0.07% of market cap — immaterial from a supply/demand perspective

insider ownershipfloat

Risk Factors

  • Insider selling could accelerate if the stock continues to rise
  • No 10b5-1 plan disclosed — sales may be opportunistic
  • Historical MAZE reports have poor T+20 performance (avg alpha -4.22%)

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
94% bullish (18 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-MAZE-1786004261996
19 reports for MAZE
Performance horizon
33% Hit rate 1 of 3 directional calls best @ T+5▲ +5.16%Jun 3, 2026
Filters
Rows
Reports for MAZE — sortable, filterable
TypeNow
Sep 4, 2026
27d ago
Insider Cluster
NEUTRAL ★ 2/10
$26.37 $24.23▼ −8.12%▼ −7.00%$26.69 (+1.20%)
Sep 4, 2026
27d ago
Insider Cluster
NEUTRAL ★ 3/10
$26.37 $24.23▼ −8.12%▼ −7.00%$26.69 (+1.20%)
Sep 3, 2026
29d ago
Insider Cluster
NEUTRAL ★ 2/10
$25.87 $24.60▼ −4.91%▼ −3.76%$26.69 (+3.16%)
Sep 2, 2026
29d ago
144
NEUTRAL ★ 2/10
$25.87 $24.60▼ −4.91%▼ −3.76%$26.69 (+3.16%)
Sep 1, 2026
4w ago
144
NEUTRAL ★ 3/10
$26.72 $24.82▼ −7.11%▼ −6.15%$26.69 (−0.12%)
Aug 17, 2026
6w ago
3
NEUTRAL ★ 1/10
$29.13 $30.42▲ +4.43%▲ +4.63%$26.69 (−8.38%)
Aug 11, 2026
7w ago
Press Release
NEUTRAL ★ 4/10
$27.53 $29.75▲ +8.06%▲ +8.51%$26.69 (−3.06%)
Aug 7, 2026
8w ago
Institutional Cluster
BULLISH ★ 5/10
$28.65 $27.18▼ −5.13%▼ −5.53%$26.69 (−6.85%)
Aug 5, 2026
8w ago
Insider Cluster
NEUTRAL ★ 3/10
$27.81 $27.53▼ −1.01%▼ −1.36%$26.69 (−4.04%)
Jul 2, 2026
13w ago
Insider Cluster
NEUTRAL ★ 3/10
$31.26 $32.42▲ +3.71%▲ +2.78%$26.69 (−14.63%)
Showing 10 of 19

US Market Status

Market Open — Closes in 3h 57m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Aug 6, 2026